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Abstract
Gene therapy essentially consists of introducing specific genetic material into target cells without producing toxic 
effects on surrounding tissue. Advances over recent decades in the surgical, radiotherapeutic and chemotherapeutic 
treatment of oral cancer patients have not produced a significant improvement in patient survival. Increasing inter-
est is being shown in developing novel therapies to reverse oral epithelial dysplastic lesions. This review provides an 
update on transfer techniques, therapeutic strategies, and the clinical applications and limitations of gene therapy 
in the management of oral cancer and precancer. We highlight the combination of gene therapy with chemotherapy 
(e.g., 5-Fluoracil) and immunotherapy, given the promising results obtained in the use of adenovirus to act at altered 
gene level (e.g., p53). Other techniques such as suicide gene therapy, use of oncolytic viruses or the use of antisense 
RNA have shown positive although very preliminary results. Therefore, further research into these promising gene 
therapy techniques is required to assess their true efficacy and safety in the management of these lesions.
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Introduction
Oral cancer (OSCC, for Oral Squamous Cell Carcinoma) is 
a genetic disease in which the genes that control cell growth 
and apoptosis are mutated, allowing cells to acquire the 
ability to invade and metastasize. Despite research efforts 
and new therapies, five-year survival has not improved over 
the past 4-5 decades. Patients with recurrent oral cancer 
that is refractory to chemotherapy or radiotherapy have 
a life expectancy of only months and the response rate to 
second- and third-line treatments is only 15% (1). 
This situation could drastically change over the next few 
years, thanks to the revolution in our knowledge of the 
disease brought about by molecular studies, which have 
already allowed us to differentiate between premalignant 
and malignant conditions (1). The introduction of new 
genes and the activation or inactivation of others may 
inhibit or suppress tumour growth (2). Gene therapy can 
potentially attack cancerous cells while respecting normal 
tissue. It may be useful to manage disease recurrence and 
as a coadjuvant therapy, e.g., in resected tumour margins. 
Clinical application of this technique in the treatment of 
oral cancer and precancer requires optimization of viral 
vectors and improvement of transfection effectiveness.
The aim of this review is to analyze the different modalities 
of gene therapy currently used to manage precancerous 
and cancerous lesions of  the oral cavity. They include 
addiction gene therapy, suicide gene therapy, immuno-
therapy, oncolytic virus therapy, inhibition of  tumour 
angiogenesis, gene deletion therapy and antisense RNA.
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Concept of gene therapy
The objective of gene therapy is to introduce new genetic 
material into target (cancerous) cells while causing no 
damage to surrounding healthy cells and tissue. It has been 
defined as the “genetic modification of cells of a patient in 
order to fight a disease”(3).  Gene therapy includes both 
the transfer of new genetic material and the manipulation 
of existing genetic material. At the present time, the most 
widely used gene therapy procedure follows these steps: (i) 
identification, isolation and amplification of the gene to 
be used in the treatment; (ii) extraction and in vitro culture 
of tissue cells from the patient to be treated; (iii) transfer 
of the therapeutic gene into these cells via a vector (Table 
1), using a gene that contains a promoting sequence to 
enable its expression and a marker to identify cells into 
which it is incorporated; and (iv) transfer into the patient 
of selected gene-containing cells. The theory is that when 
the gene exerts its normal physiological functions, the 
disease will be eliminated. 
Gene therapy approaches to oral cancer and precan-
cer
OSCC is a good candidate for gene therapy because 
primary and recurrent lesions are readily accessible for 
injection or application of the agent (3). Current gene 
therapy approaches include:
- Addiction gene therapy:
The aim of this approach is to regulate tumour growth 
by introducing tumour suppressor genes that inactivate 
carcinogenic cells. Numerous studies have described p53 
alteration as an early event in oral cavity carcinogenesis, 
and mutated p53 expression is frequently observed in non-
cancerous epithelium adjacent to OCSS (4). Moreover, 
the percentage of epithelial cells expressing mutated p53 
is usually higher with greater severity of  the epithelial 
disorder. For these reasons, one of the tumour suppressor 
genes most commonly used in gene therapy is the p53 
gene, and numerous viral vectors, especially adenoviral 
vectors, have been developed for its application. Table 1 
VIRUS  ADVANTAGES DISADVANTAGES 
RETROVIRUS 
 
-Well known, easily managed 
- Includes up to 9 kb of exogenous 
genetic material 
- Efficient transfer and high levels of 
expression 
- Integration in genome  ensures 
permanent expression 
- Infects only cells in 
division; low transduction 
efficacy 
- Possible insertion 
mutagenesis 
- Low titres 
- Possible generation of 
infective viruses 
ADENOVIRUS 
 
- Infects dividing and resting cells; 
high transduction efficacy 
- Includes up to 7.5 kb of exogenous 
genetic material 
- High titres 
- Does not integrate in the genome, 
which avoids insertion mutations 
- Transitory expression; 
anti-adenoviral immunity 
may be less effective, 
requiring periodic 
treatments 
- Lower expression  levels 
- Possible immune and 
inflammatory reactions 
- Risk of multiplication 
ADENO-
ASSOCIATED 
VIRUSES (AAV) 
- High transduction efficacy - Difficult to prepare 
HERPESVIRUS 
- Thymidine kinase expression; high 
efficacy of gene transfer 
- Capable of inserting large foreign 
DNA sequences and producing long-
term latent diseases 
- Capable of distributing genes to 
pluripotent cells and their 
differentiated progeny 
-  Relative toxicity 
-Gamma-herpes viruses are 
sometimes related to 
malignity 
 
 
 
Table 1. Most frequent vectors in gene therapy (Taken from Smith, 1995) (30).
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E17
summarizes the most used vectors in gene therapy, with 
their advantages and disadvantages. 
Some authors analysed the efficacy of gene p53 to inhibit 
tumour growth as a function of the use or not of adeno-
virus vectors with replicative capacity. Results showed 
that efficacy was higher when the replicating vectors were 
used, although the reasons for this improvement are not 
fully understood (5).  A phase III study is currently under 
way on adenovirus vector Ad5CMV-p53. This is applied 
by intramucosal injection followed two hours later by 
a mouthwash. From the next day, it is administered as 
a mouthwash twice a day for 2-5 days. This treatment 
is repeated every 28 days and has shown a capacity to 
inhibit disease progression in precancerous lesions with 
no toxic effects (6). 
Other tumour suppressors introduced into tumour cells 
by gene transfer are Rb (retinoblastoma gene) and mda-
7 (melanoma differentiation-associated gene-7). Their 
effects on apoptosis and tumour growth appear to be 
similar to those of interleukin-24 (Il-24), a Th1 cytokine 
that triggers an anti-tumour and pro-apoptotic response 
in the immune system (7).
Gene transfer of gene p27 was found to inhibit the cell 
cycle of tumour cells, inducing apoptosis and triggering 
the suppression of tumour growth. It has been demons-
trated that gene p27 mutations are highly related to the 
appearance of tongue cancer. According to these results, 
the therapeutic use of p27 gene may in the future prove 
useful for the treatment of OSCC (8).
Recent mouse studies found that the intratumoural injection 
of Allovectin-7® (Vical Inc, San Diego, USA), suppressed 
the growth of head and neck tumours. Allovectin-7 is the 
result of gene transfer, i.e., co-expression of the human gene 
of the HLA-B7 leukocyte antigen with beta2-microglobulin 
gene. This treatment appears to be relatively well tolerated, 
with only mild or moderate reactions around the injection 
site that are reduced after the second injection. However, 
further studies are required since only preclinical trials in 
mice have been performed to date (9). 
Gene therapy using oncolytic viruses
One of the most promising gene therapy approaches is the 
use of viruses that replicate only tumour cells, designated 
oncolytic viruses. This procedure emerged from the dis-
covery of adenoviruses lacking E1B, which did not grow 
in normal cells but grew in cells without p53, one of the 
most common characteristics of tumour cells. Adenovirus 
ONYX-015, which presents deletion of the E1B region, 
has been used to control OSCC lesions (10).
The release of an oncolytic herpes virus in a primary tumour 
after its surgical excision appears to significantly reduce 
the tumour and regional metastasis (11). Therefore, the 
virus must be genetically modified to attenuate its toxicity 
in normal tissue while maintaining its oncolytic activity 
against malignant tumours, with the aim of reinforcing 
safety without compromising the anti-tumour efficacy 
of the virus (7). Replication of ONYX-015 adenovirus is 
minimal in cells with normal p53 function but reaches high 
levels in cells with p53 alterations or mutations. Intrave-
nous injection of this vector produces important tumour 
regression and improves survival in presence of metastasis. 
These oncolytic viruses have shown enhanced activity when 
combined with chemotherapy. Thus, the use of ONYX-015 
alone had an efficacy of 20%, which was increased by up to 
6% in combination with 5-fluoracil (5FU) (12). Presence of 
cytokines IL-6, TNF-α, IL-10 and IFN-γ is observed at 24 
hrs after ONYX-015 administration. IFN-γ levels increase 
after four days, while TNF-α levels increase after six hrs, 
thereby contributing towards the appearance of an immune 
response to the tumour (13). 
Patients with precancerous lesions were treated with Ad-
vexin® mouthwash (Introgen Therapeutics, Inc (INGN), 
NY), which also administers p53 by means of an adeno-
virus. Tissue analyses before and after treatment showed 
a marked decrease in the number and aggressiveness of 
precancerous cells. This treatment, currently in a phase II 
trial,  also appears to be very well tolerated (14). Rudin 
et al tested three different dose and duration regimens in 
19 patients with epithelial dysplasia. After a 30-month 
follow-up, complete remission was recorded for one of 
the three patients who received the highest dose of the 
virus (mouthwash) for the first 5 days followed by weekly 
administration for 5 weeks. Response of p53 function was 
assessed by determining p53 protein expression, which 
was significantly suppressed in patients who responded 
to treatment but not in non-responders (15).  
Other researchers have reported on the anti-tumour effi-
cacy of the intravenous injection of oncolytic adenovirus 
OAS403. Cytotoxicity appeared in tumour cells at 7-10 
days after exposure to this adenovirus. This adenovirus 
is especially active in tumours with alterations in Rb 
protein and in the regulation of telomerase expression. 
This adenovirus has proven to be selective, innocuous and 
efficacious in both in vivo and in vitro trials, and its syste-
mic administration has been shown to be highly effective 
against tumours in mice (16). Again, the combination of 
OAS403 with conventional chemotherapeutic agent, e.g., 
liposomal doxorubicin, increased the anti-tumour efficacy 
in preclinical studies, and Phase III trials are now under 
way. Table 2 summarises current gene therapies that use 
oncolytic viruses.
- Suicide gene therapy:
In suicide gene therapy, genes are introduced that stimu-
late the generation of products that are toxic for the cells. 
When suicide genes are used in retroviral vectors,  protec-
tion measures must be taken against the appearance of 
oncogene-activating mutations (3). Suicide genes permit 
the expression of enzymes that can transform non-toxic 
drugs into cytotoxic substances. Thus, the thymidine 
kinase gene of Herpes Simplex Virus (HSV) transforms 
ganciclovir into ganciclovir phosphate (2).
E18
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Suicide gene therapy can also use adenoviruses, although, 
as mentioned above, some characteristics of these vectors 
limit their efficacy and safety (Table 1) (17). Nevertheless, 
gene transfer of HSVtk gene (Herpes simplex virus thy-
midine kinase gene) via adenovirus vector in combination 
with ganciclovir administration may be a good therapeutic 
option for OSCC (18).
One of the main drawbacks of suicide gene therapy is 
the poor distribution of the vector within the tumour. 
Although a relatively low anti-tumour response has been 
observed in clinical trials because of poor transfection effi-
cacy, a high percentage of transfected cells do not appear 
in vivo due to their ability  to induce tumour death (3).
Considerable knowledge is now available on genes that 
contribute towards resistance against chemotherapy, in-
cluding MDR1 (Multidrug resistance protein 1), MRP1 
(Multidrug Related Protein) and DHFR (Dihyfolato-re-
ductase) (19). In these cases, gene therapy has three main 
objectives: action at tumour angiogenesis level; protection 
of normal tissue, especially medulla, from toxic effects of 
chemotherapy; and enhancement of the immune system 
(2). (See Table 2)
- Introduction of genes to inhibit tumour angiogenesis
Research is in progress on the use of microencapsulated 
cells in antiogenic cancer therapy. The technique consists 
of the release of therapeutic proteins to encapsulate re-
combinant cells. Microcapsules are designed to be permea-
ble to recombinant products and nutrients but not to host 
immune mediators, due to their large size. These cells are 
capable of secreting angiostatin, an important angiogenic 
inhibitor. Angiostatin receptors present ATP synthase on 
the surface of human endothelial cells, as in the case of 
αvβ3-integrin and vitronectin. This enables angiostatin 
to be localized in the tumour instead of organs near the 
implantation site of the capsule. However, this technique 
is not adequate for long-term removal of  the tumour, 
especially when it is in an advanced stage. Moreover, it is 
a prolonged therapy that requires repeated doses and is 
associated with a high degree of toxicity (20).
Investigators are also developing vaccines against receptor 
2 of the VEGF factor (Vascular Endothelial Growth Fac-
tor), also known as FLK-1, with the resulting inhibition of 
angiogenesis, tumour growth and metastasis. Studies have 
demonstrated that the vaccine against FLK-1 is effective, 
stimulating T lymphocytes that inactivate this receptor 
and, therefore, vascularisation of the tumour. This vac-
cine also appears to be useful in the treatment of tongue 
metastasis of OSCC, with an increased immune response 
observed at 10 months of the inoculation (21). 
- Immunotherapy 
The aim of immunotherapy is to increase the patient’s 
immune response to the tumour. Patients with OSCC pre-
sent altered function of immune cells, including NK cells, 
T lymphocytes and numerous cytokines. Thus, animal 
studies have shown that IL-2 administration  activates T 
lymphocytes and NK  cells and that these in turn activate 
tumour necrosis factor α (TNF-α), triggered by the strong 
tumour inhibition effect (3).
Mechanisms to increase the sensitivity of the tumour to 
normal therapeutic processes are under investigation. 
Radiosensitivity to γ radiation and chemosensitivity to 
5-fluoracil (5-FU) were reported in OSCC after suppres-
sion of NF-kB activity, which activates the antiapoptotic 
proteins TNF, TRAF-1, TRAF-2 and cIAP-1. NF-kB also 
increases the expression of proinflammatory cytokines, 
e.g., IL-1α, IL-6 and IL-8, and of enzymes that degrade 
matrix metalloproteinase-9 (MMP-9). NF-kB appears 
to contribute towards the progression and metastasis of 
various cancers, including OSCC,  therefore its inhibi-
tion may be a useful coadjuvant treatment in oral cancer 
therapy (22).
Other studies have addressed the transduction of IL-2 
gene, which appears to have an anti-tumour effect, by 
using the mutated fibroblast of  an adenovirus and an 
RGD peptide (Adv-F/RGD) (23). The intratumoral 
injection of  Adv-F/RGD showed a high anti-tumour 
effect due to increased mononuclear cell infiltration and 
major necrotic changes. It also achieved local control of 
the disease, an essential objective since most deaths result 
from metastasis. The development of a new gene therapy 
for the local treatment of oral cancer would be extremely 
valuable (24).
Ongoing research has reported that adenoviruses OW34, 
E1B55KD and HSV-TK were more effective in combina-
tion with ganciclovir than when used alone (3). 
Another therapeutic approach may be to use the monoclo-
nal antibody Anti-ICAM-2 alongside the intratumoural 
gene transfer of interleukin-12. ICAM-2 is a glycosylated 
protein with surface adhesion that is expressed in endothe-
lial cells and activates lymphocytes. Recent studies found 
that systemic administration of Anti-ICAM-2 induced 
the complete regression of OSCC lesions. However, the 
tumour regression is dependent on the immune system 
function and the induction of specific tumour toxins by 
the action of CD8 lymphocytes (25).
Gene transfer of IL-12 using plasmid pNGVL3-mIL12 is 
also being investigated. An FDA-approved clinical trial is 
under way but it is too early to predict results (26). (See 
Table 2)
- Excision gene therapy 
The aim of this therapy is to remove defective oncogenes, 
thereby inhibiting the growth of tumour cells. Thus, the 
efficacy of using akadaic acid to suppress Egr-1 (early 
growth response factor 1) protein expression is being stu-
died in the OSCC setting. Okadaic acid is a highly toxic 
polyether that inhibits phosphorylation of types 1 and 2A 
proteins, reducing expression of Egr-1 and thereby trig-
gering the inhibition of tumour activity, since it is related 
to cell proliferation and division. Inhibition of Egr-1 may 
represent a good therapeutic approach, since genes that 
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GENE OR LEVEL 
OF ACTION 
VECTOR 
USED/APPROACH 
MECHANISM OF 
ACTION 
MEANS  OF 
ADMINISTRATION AUTHOR/YEAR 
Mutated or altered 
P53 
Adenovirus 
ONYX-015 
Increases replication in 
cells with altered p53 
(OSCC) by using 
adenovirus or ONYX-
015 
Intravenous injection 
Alone, plus 5-fluoracil or 
plus IL-2 
Nemunaitis et al, 2003 
Mutated or altered 
P53 
Adenovirus 
ONYX-015 
Reduction of 
leukoplakias Mouthwash: Advexin® Nemunaitis et al, 2000 
Alteration of Rb 
protein 
OAS403 
Controls expression of 
gene E4 and decreases 
in vivo and in vitro 
toxicity 
Alone or plus Doxil® 
(chemotherapeutic) 
Ryan, 2004 
MnSoD gene Addiction G.T 
Suppresses tumour 
malignity by reducing 
peroxide flow and 
therefore cell mitosis 
------------------------ Liu et al, 1997 
tKHSV gene Suicide G.T Increases apoptosis ---------------------------- Fukui et al, 2001 
MDR1, MRP1, 
DHFR 
Suicide G.T 
Reduces tumour 
angiogenesis, increases 
apoptosis, modifies 
immune system 
---------------------------- Gottesman, 2003 
4-1BB gene Immunotherapy 
Activation of T 
lymphocytes ------------------------------ Cheuck et al, 2004 
Anti-ICAM-2 Immunotherapy 
Complete regression of 
oral cavity tumours  Pérez et al, 2002 
Intratumoural 
injection of Adv-
F/RGD 
Immunotherapy 
Increases anti-tumour 
effect by local control 
of the disease 
---------------------------- Dehari et al, 2003 
Table 2. Gene therapy approaches in oral cancer and precancer. 
MnSOD: Manganese Superoxide Dismutase
tKHSV: Thymidine kinase gene of the Herpes Simplex 
Virus
MDR1:  Multidrug resistant protein 1 
MRP1: Multidrug related protein
DHFR: Dihydrofolate-reductase
GT: Gene Therapy
E20
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control cell growth and cell cycle progression, including 
those that encode for tissue factors TGF-β1, PDGF-A 
and PTEN, are regulated by the expression of this protein. 
Some authors demonstrated that inhibition of  protein 
kinase C reduces the expression of this gene, triggering 
higher sensitivity of the tumour to radiotherapy (27).
- Antisense RNA
Gene expression can generally be inhibited by RNA, which 
is complementary to the DNA. Antisense RNA may pre-
vent the activity of oncogenes, including myc, fos and ras; 
and it can also inhibit viruses, e.g., HSV-1, HPV (Human 
Papillomavirus) and HTLV-1 (Human T-lymphotropic 
virus). Conventional use of this technique is limited by the 
difficulty of introducing a sufficient quantity of antisense 
molecules to inhibit tumour growth. Powerful promoters 
are currently being developed to overcome this drawback. 
Thus, preclinical studies using antisense sequences under 
the control of six small RNA promoters demonstrated a 
powerful anti-tumour effect with minimum toxicity (28).
A phase 1 trial is under way in patients with advanced 
oral cancer to evaluate the safety and biological effects 
of administering liposome-mediated intratumoral EGFR 
(Epidermal Growth Factor Receptor) by means of anti-
sense gene therapy. Results have been positive, showing a 
low toxicity and high efficacy (29).
In general, positive outcomes have been reported for gene 
therapy (30). Only three adverse effects have been associa-
ted with gene therapy in oral cancer, including one death. 
It should also be borne in mind that patients undergoing 
this type of  treatment are usually in a very advanced 
phase of the disease, and it can be difficult to distinguish 
whether the gene therapy or the cancer is responsible for 
adverse effects (3).
The most frequently observed adverse reactions are severe 
inflammatory processes and coagulopathies, generally in 
relation to the viral vectors employed. In order to predict 
these effects, the FDA and NIH have developed a program: 
The Genetic Modification Clinical Research Information 
System (GeMCRIS) www.gemcris.od.nih.gov/, an accessi-
ble web-based system that compiles and analyses all data 
related to gene therapy (2).
Conclusions
As shown in this review, research on gene therapy in oral 
cancer is increasing in the laboratory and in the clinical 
settings. In the medium- and long-term, it may contribute 
a definitive treatment for oral cancer and precancer that 
offers greater effectiveness compared with current thera-
pies and markedly reduces the high mortality associated 
with these lesions. At present, the use of adenoviruses 
to act at altered gene level and the combination of this 
technique with chemotherapy or immunotherapy appear 
to be the most promising approaches to the management 
of oral cancer and precancer.  
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